Pharmaceutical giant Novo Nordisk forfeited patent protection for semaglutide – the active ingredient in blockbuster diabetes and weight loss drugs Ozempic and Wegovy – in Canada after failing to pay a $450 maintenance fee in 2019. The company had paid maintenance fees through 2018 but requested a refund for the 2017 fee, apparently seeking more time to decide whether to continue protecting the patent.

Archived version: archive.is/…/novo-nordisk-loses-canadian-patent-p…

Disclaimer: The article linked is from a single source with a single perspective. Make sure to cross-check information against multiple sources to get a comprehensive view on the situation.